Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,530
-250 (-1.41%)
Apr 28, 2026, 3:30 PM KST
53.10%
Market Cap 1.62T
Revenue (ttm) 1.27T
Net Income (ttm) -109.88B
Shares Out 92.50M
EPS (ttm) -1,637.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 297,465
Average Volume 308,588
Open 17,780
Previous Close 17,780
Day's Range 17,520 - 17,790
52-Week Range 9,690 - 23,950
Beta 0.79
RSI 45.35
Earnings Date May 14, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 278
Stock Exchange KOSDAQ
Ticker Symbol 085660
Full Company Profile

Financial Performance

In 2025, Chabiotech's revenue was 1.27 trillion, an increase of 21.36% compared to the previous year's 1.05 trillion. Losses were -109.88 billion, 2206.6% more than in 2024.

Financial Statements

News

There is no news available yet.